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See related research by Zampieri et al., http://ccforum.com/content/19/1/150I read with interest the recent systematic review of
nebulized antibiotics for ventilator-associated pneumonia
[1]. I congratulate and applaud Zampieri and colleagues’
important work, but several important issues should
be noted.
First, there is one important methodological issue with
the review. The data from randomized controlled trials and
observational studies were inappropriately pooled together,
which goes against the precept of pooling studies with
similar design. In fact, the pooling of data from randomized
controlled trials and observational studies is only recom-
mended for the assessment of harm/adverse effects. Thus,
results from randomized controlled trials and results from
observational studies should be separately pooled.
Second, two of the included observational studies were
case–control studies [2, 3], and therefore using the relative
risk as the summary statistic is improper. Instead, the
odds ratio should be used as the summary statistic to pool
data from observational studies.
Third, the authors used the standardized mean difference
as the summary statistic for the continuous variables. As
we know, the standardized mean difference is unitless
because it is a relative, rather than an absolute, measure of
effect. Instead, the authors should have used the mean
difference.
Last, Kalin and colleagues’ study should be excluded
from the review. This study does not state why patients
received inhaled colistin and how many patients received
a high, normal or low dose in the inhaled plus intravenous
colistin group and the intravenous colistin group [4].
Inadequate allocation may thus exist, resulting in aCorrespondence: wanjiegu@hotmail.com
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unless otherwise stated.significant potential for selection bias. Inclusion of this
study leads to significant heterogeneity, as shown in the
forest plot for clinical cure.
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